Oxford Biomedica Share Price (OXB)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Oxford Biomedica	LSE:OXB	London	Ordinary Share	GB0006648157	ORD 1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.06p	+1.13%	5.36p	5.36p	5.44p	5.56p	5.30p	5.40p	3,581,445	16:35:22

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	27.8	-20.3	-0.6	-	165.54

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), Valirx (VAL), Port Erin (PEBI)

Oxford Biomedica (OXB) Latest News (1)

Oxford Biomedica News

Date	Time	Source	Headline
23/6/2017	10:12	UKREG	Oxford Biomedica PLC Director Dealings / Market Share Purchase
14/6/2017	15:15	ALNC	Oxford BioMedica Notes Novartis' Positive Trial Results For CTL019
14/6/2017	15:05	ALNCF	Alliance News Flash Headline
14/6/2017	15:00	RNSNON	Oxford Biomedica PLC Findings from Phase II JULIET Study
07/6/2017	17:41	GLOBE	Oxford BioMedica plc: Oxford BioMedica notes FDA Advisory Committee to..
07/6/2017	10:35	ALNC	Oxford BioMedica Notes US FDA Meeting Date Set For Novartis's CTL019
07/6/2017	07:01	RNSNON	Oxford Biomedica PLC OXB notes FDA Advisory Committee to review CTL019
02/6/2017	07:00	UKREG	Oxford Biomedica PLC OXB to Present at Jefferies Healthcare Conference
01/6/2017	12:22	UKREG	Oxford Biomedica PLC Total Voting Rights
24/5/2017	13:55	UKREG	Oxford Biomedica PLC Director/PDMR Shareholding

More Oxford Biomedica News

Oxford Biomedica Takeover Rumours

Oxford Biomedica (OXB) Share Charts

1 Year Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

Intraday Oxford Biomedica Chart

Oxford Biomedica (OXB) Discussions and Chat

Oxford Biomedica Forums and Chat

Date	Time	Title	Posts
24/6/2017	08:54	Oxford Biomedica Bulls Only Thread	24,247
22/6/2017	16:43	OXFORD BIOMEDICA (OXB): MODERATED CHART AND DISCUSSION THREAD	72,848
21/1/2017	19:55	Only worth 1.25p on fundamentals....	19
24/12/2015	15:10	Oxford Biomedica Bears Only thread	5
18/7/2014	13:56	Welcome To The Greatest Short On ADVFN Sponsored By tony979 !	41

Add a New Thread

Oxford Biomedica (OXB) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Oxford Biomedica trades in real-time

Oxford Biomedica (OXB) Top Chat Posts

Date	Subject
24/6/2017 09:20	Oxford Biomedica Daily Update: Oxford Biomedica is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 5.30p. Oxford Biomedica has a 4 week average price of 4.91p and a 12 week average price of 4.44p. The 1 year high share price is 5.90p while the 1 year low share price is currently 3p. There are currently 3,088,420,525 shares in issue and the average daily traded volume is 1,756,660 shares. The market capitalisation of Oxford Biomedica is £165,539,340.14. Read Full Thread Reply
22/6/2017 15:43	rrr: While I agree the main point is about patients, as you ask I think it will get approval and that that will be good for OXB share price (but to what extent I leave to others). rrr Read Full Thread Follow Reply
22/6/2017 12:05	rrr: marcus thank you! I am just so excited by this, it is so utterly amazing. I'm not talking about the OXB share price, I'm talking about the medicine and the patients, who could easily be any of us. These are sounding suspiciously like cures - for the previously incurable. utterly amazing and wonderful Read Full Thread Follow Reply
31/3/2017 19:04	sddavies1: Its a frustrating shame that, despite Novartis delivering on their promises for something that is key to our future, the OXB share price is still languishing below its recent highs.Instead of remaining silent. Its high time BoD started to make noises about how they plan to deal with the debt that has cast a shadow over proceedings.I know that everything is starting to look rosy on paper but to me it seems that unless they start to add capital value soon, we will be sittings ducks for a nice cheap buy out. Read Full Thread Follow Reply
31/3/2017 08:54	marcusl2: Here is the biggy....................... They are assuming OXB receives 4% royalties on CTL019 ! We estimate that Novartis will achieve sales of $2.05bn per annum from CTL-019 by 2025. OXB could, therefore, receive a total of $82.0m in royalties per annum, in addition to manufacturing revenue. OXB-102 OXB-102 should be in sales by 2030. Time is needed to secure a partner (2H-‘17E), complete clinical trials (2028E), and achieve market authorisation. An estimated 610k people over 50 years of age will have Parkinson’s in the US, and 1,200k in Europe, by 20304 . We estimate that OXB-102 could reach $1.8bn annual sales in EU and US; assuming 10% royalties, OXB will make $181m per annum plus manufacturing fees. This is based on the following assumptions: Assuming 50% penetration rate at peak in US and EU, OXB-202 could be grafted into around 4,300 patients per year. At a price of $20k per cornea, and 10% royalties to OXB, OXB could receive $8.6m annually. This would increase as the product enters additional markets, such as low-risk and first-time corneal grafts. On this basis, it would be rational to apply an EV/sales multiple of 4-5x to OXB’s bioprocessing business service business, especially when it is being validated and underpinned by Novartis. This would imply an EV of ca.£188-£;235m based on future sales, just for this part of the business. , Hardman estimates that OXB has a risk-adjusted valuation of 7.5p per share. Further positive news flow from Novartis on CTL109 – successful completion of trials – would change the riskadjustment and increase the valuation, suggesting that this share price level is likely to be reached relatively quickly. The book value of the GMP manufacturing and HQ fixed assets, £27.5m, is assumed to be inherent in the EV/sales multiple. Read Full Thread Follow Reply
26/3/2017 16:23	beanol: Yes Harry. Agree your last para. But sadly it seems ref Oxb share price wise the market has become, because of the various disappointments and non fulfilments of 'promises' very binary/empirical. Has to be concrete events rather than expectation that will drive it up of which the expected Novartis FDA filing is the first challenge. Read Full Thread Follow Reply
30/1/2017 19:38	beanol: Yes Marcus indeed. Very promising. BUT why with all this positive news and it being fairly clearly known that Oxb has a role to play which will hugely benefit the company has there been no upwards movement in the Oxb share price - aren't markets supposed to rise ahead of major announcements? Or is the market so mistrustful of Oxb management and its past record that..... Read Full Thread Follow Reply
22/1/2017 01:10	beanol: HarryFrom reading your always thoughtful and considered posts for years I know you have a deep well of understanding about Oxb which the rest of us profit from and I certainly for one will never rival or come near. But right now (2017) there's a business imperative on the march - Novartis and Car T therapy : I am clear from a combination of the following: letter LT wrote following two specific complaints I made, speaking to people connected to Novartis, others involved in the haplessly managed fund raising last year that this year if not now or never for Oxb will certainly be pretty critical for the company. No substantive progress for Novartis no progression for Oxb share price. But if progress for Novartis and Car T then we get into a virtuous circle which will per force mean a closer relationship or more with Novartis. Given what the latter have riding on Car T there is likely to be no other alternative. I can't believe Trovax or any other drug from Oxb's stable will (really) come into the reckoning. Time will tell obviously but let's see where we are end of April. In writing this I realise I am becoming a one trick pony but in spite of its pretensions to wider success so I'm afraid Oxb may be becoming too. Read Full Thread Follow Reply
03/1/2017 14:27	beanol: Ref Harry's previous few posts and Marcus's dreams I offer the following:What success looks like obviously evolves and morphs for most companies and especially one like Oxb which unfortunately seems mired in permanent adolescence. But it seems to me that, if we are lucky, we are approaching an inflection point which will decide the future of the company and our lot as shareholders. That inflection point is the filing in Q1 2017 with the US FDA for CTL019. If this process goes smoothly Novartis will surely want to tie down all key elements in the development and production chain of which Oxb is one part. If this happens Novartis will further want all these key elements to come under their governance and tech criteria - which is likely to mean them wanting to either take a bigger stake in Oxb or buying the whole company. Should this happen the multiple may be unlikely to be in the realms of 50x but could comfortably see us having an share price in the order of 20p plus. Quite a few posters have made the point that they want Oxb's own drug pipeline to take pride of place and that this is why they invested in Oxb. Fair point. Me too. But I don't think this is 'real world' thinking - given we are where we are - especially when there is an attractive and viable alternative path. Besides which, how would Oxb finance continuing to go its own way - the last fund raising was a fiasco or actually worse given the way JD handled it ie beyond incompetent and he should surely have lost his job for that? The fact remains that Oxb has lost the confidence of the market and will have difficulty raising further funds without clear breakthroughs. Posters have also made the point that Oxb becoming a largely manufacturing company will further depress the SP/expectations - well yes to some extent but Oxb is not manufacturing paracetamol. Its Oxb's hi tech specialised delivery process which provides the platform which allows the whole Novartis chain to work - they couldn't replicate this speedily. Simpler and more efficient to bring Oxb in house. If there's progress this year on e.g. Trovax then great but I'm confident it is developments in CTL019 and Novartis's decisions which has the best chance of us seeing Oxb end 2017 on a multiple of the current share price or even better. Read Full Thread Follow Reply
20/6/2016 23:09	philh75: Anyone concerned about the potential shock impact of a leave vote to oxb share price, or uk shares in general? Read Full Thread Follow Reply
30/4/2016 22:19	harry s truman: Doc, Interesting point re replacement on the same terms. I think the actual terms are very much secondary in most people's minds - we all accept these days that CEO's will generally pay themselves whatever they can - it's the performance of the share price which is the metric for most people. If the share price performance was good then the money to JD would be no issue for most. I've nothing against JD personally. I've disagreed with some of the decisions that he has made, but at the end of the day I am a shareholder typing on a BB and he is a CEO with a room full of advisers. It's unlikely that I'm the one who knows best and I simply have to hope that he acts on the best available advice. However, shareholder inclusiveness under him is the pits. We were probably spoiled somewhat by the previous regime, but these days what we get appears to be the absolute minimum that he can get away with. Even the Edison reports seem to have dried up now. Until recently we were able to bypass the stonewall of OXB and keep track of recruitment in the TroVax trials via that UKCRN website, but that seems to have closed down and so now we will have no idea on the progress of any of these trials until OXB deem to make an announcement (or not). Had JD made a serious effort to make us feel included then he would have gained an awful lot of goodwill on here. As it is though, there are now plenty of people who look how much money he earns with his salary, his bonuses, his share options and such, before pondering (often out loud) his actual value to us given the share price. He hasn't done himself any favours in that respect. I think it was yourself on here a long time ago who told us that JD's big claim to fame was being tasked with buying a European division for Cephalon, but following that shopping spree he and them seemed to part company. Perhaps I've not got that 100%, but I certainly remember the OXB appointment notice quoting a turnover figure for the division that he grew for Cephalon (which I assume means acquired for them). I'm sure he's a bright chap, but he just doesn't ever come across as a CEO that you'd want to have interviewed by Paxman or facing a house of commons committee. If he was in the right place at the right time during some tumultuous events for OXB then good luck to him, but that doesn't mean that we owe him a living forever. Should OXB ever make that leap from biotech drug development (and now contract manufacturing / technology partnering) into a pharmaceutical company with its own licensed drug (not impossible - others have done it) then I could easily foresee a situation where Martin and the other major shareholders would thank him for all of his hard work during the transition, pay him up whatever his evergreen and his options are worth, then introduce the man or woman to guide the company through its next phase. Anyway, that aside and for what it's worth, I'm still very positive about OXB. I think we're in much better shape than we have been for years. I have this idea (and it might be Pram who intimated this - but apologies if it wasn't) that we were told in the past that OXB weren't chasing Lentivector contracts too hard as the Novartis deal basically tied everything up. This seemed to be confirmed by OXB directly in the placing RNS, when they explained that production income for H1 2015 was hit whilst they produced the clinical trial material for our upcoming ProSavin trial. In other words they couldn't produce Lentivactor for CAR-T engineering for Novartis and Lentivector for ProSavin gene transport simultaneously. They didn't have the capacity and thus only H2 2015 had full production Novartis earnings. They explain in the results this week that "our cGMP clean room capacity has more than doubled to 950m2. We are expanding this capacity further, and with the recent completion of GMP2 will have three independent production suites totalling 1,200m2.". So there are several ways to look at this:- We could now work on our in house drugs and those for Novartis simultaneously (but unless RetinoStat needs new dose levels it's hard to see the immediate need for that). We could simply expand our production for Novartis which in round figures was £10m for H2 2015 on the original capacity - not the 2 stage expansion to 950 or 1200m2. But more likely to me is that we very quickly now bring on-board another Novartis type contract from one of the many companies that have been using our Lentivector on a research licence. There are a lot of them and some will go into the clinic. I think this / these are what OXB are hinting at when they say in the results that "Our work with Novartis has enhanced our credibility in the sector and we are in discussions with a number of third parties working in a variety of cell therapy areas to provide such services and IP licences". Then later they add "Partnering revenues should continue to grow strongly in 2016" and in the outlook they say that "we plan to advance our integrated business through a number of inflection points." To me that says another manufacturing partner is in the wings - and I remember what share price we went from and to following the Novartis deal. This also fits with the idea of a small agreed placing to get us to a certain point (which seemed a very precise sum) prior to a much bigger open offer at a much higher price - possibly to get rid of the Oberland loan facility and clear the decks of the manufacturing expansion costs. Whether it's a large increase in manufacturing earnings from Novartis or another manufacturing partner / new partners - or both - it doesn't really matter to me. Hoping for both doesn't seem to be unrealistic. Read Full Thread Follow Reply

Oxford Biomedica share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:42 V: D:20170624 17:36:39